NEW YORK, May 6, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in ...
According to the Boston Business Journal, ALS Therapy Development Institute has agreed to a 33,310-square-foot lease at 200 ...
Acting US Food and Drug Administration (FDA) Commissioner Ned Sharpless on Thursday announced that the agency would finalize guidance on developing treatments for amyotrophic lateral sclerosis (ALS) ...
Athira Pharma, Inc. has announced favorable results from a Phase 1 clinical trial of its drug candidate ATH-1105, which targets neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). The ...
Degradation of motor neurons, conceptual computer illustration. Motor neuron diseases are a group of neurodegenerative disorders Amyotrophic lateral sclerosis (ALS) is the most common of the motor ...
Cambridge, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), ...
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical ...
─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in ...
Funding aims to bring high quality ALS care closer to home and more accessible for people living with ALS nationwide "Thanks to this transformational gift, we are able to support clinical programs ...
HERSHEY, Pa. — A toxic version of a certain protein may affect brain, spinal cord and skeletal muscle tissues differently, leading to the complex development and progression of amyotrophic lateral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results